Tweet
There are not very many details on Genia's website, but what little is there reads like a carbon copy of Oxford's stuff.
So how does this not infringe on everything Oxford is doing?
-
There are not very many details on Genia's website, but what little is there reads like a carbon copy of Oxford's stuff.
So how does this not infringe on everything Oxford is doing? -
Don´t know the answer. Only that Life technologies has put alot of money on it!
It is under my radar! -
I smell a patent war!Comment
-
Interesting interview with their CEO here.
Sounds very, very, very much like ONT. Beta's out at the end of the year, commerical in 2013.
Now, one of the most interesting things is that he's quoting price ranges. Sub-$100 disposable chips and sub-$1k chip readers (about 9:30 in the vid and again at 14:30).Comment
-
He seems to think a lipid bilayer is a cell wall.--------------
EthanComment
-
I can't comment on the IP issues (there seems to be so much nanopore IP out there, I don't know how they all keep it straight), but what Genia claims to have over other nanopore companies is their expertise in using analog-to-digital sensors directly on integrated circuits. They say it gives them control over the creation of lipid bilayers, the addition of the protein nanopore, and precise control over the movement of the DNA molecules (back and forth through the pore for multiple reads). They also claim to be able to ramp up to 1M sensors (each with an individual pore) on a 1cm X 1cm chip.
I love what ONT is demonstrating with how their instruments can operate in tandem, but it isn't clear how many independent sensors/pores they'll have per well. Does anyone know?
I've placed what I know about Genia and ONT on BlueSEQ's knowledgebank (along with a dozen other emerging NGS technologies): http://blueseq.com/knowledgebank/emerging-technologies/Comment
-
I'm still waiting for Starlight...Comment
-
Yeah, I don't think I'd hold my breath on that one...Originally posted by Elcannibal View PostComment
-
They are presenting tomorrow/today I think, we shall see. My prediction is "not very many". Hope I am wrong.Originally posted by scbaker View PostComment
-
-
Not yet, but they should be. I would love to hear more details about how the Q-SEQ device will work. Feel free to contact me directly.Originally posted by Biotech Rockstar View PostComment
-
-
A group at the Salk presented data at AGBT13 using modified Starlight (no quantum dots).Originally posted by scbaker View PostComment
-
Very interesting. Do you know if they've purchased the IP from $LIFE or if they have any commercialization plans?Originally posted by krobison View PostComment
-
Roche gets back in the NGS game with purchase of Genia
After effectively exiting the NGS market in 2013, Roche is making moves to get back into it with their acquisition of Genia for up to $350M ($125 up front and $225 in potential future payments). Read more on our blog.Originally posted by BBoy View PostComment
-
I’m not a sequencing expert. I’m a purification scientist who uses NGS to evaluate workflows my group develops. With this perspective, we think about the sample first and the NGS workflow second. The sequencer is an exceptionally honest reporter, but it can only report on what you give it, so whether you get clean, interpretable data from an NGS workflow is largely determined before you begin.
Here are nine questions we think about, in roughly the order they matter, before...06-18-2026, 07:11 AM -
Data variability is still an issue in sequencing technologies despite the advances in reproducibility and accuracy of these platforms. But the problem does not originate in the sequencing itself, but in the previous steps, before the sample reaches the sequencer.
The first step is collection, followed by preservation and sample preparation for analysis. Most scientists overlook those steps, but not being careful might just be skewing the experiment’s results.
...06-02-2026, 10:05 AM -
With the launch of new single-cell sequencing platforms in 2026, the field stands at an exciting inflection point. This article surveys the most impactful advances in the field and discusses how they’re reshaping research in cancer, immunology, and beyond.
Introduction
Single-cell sequencing technologies have undergone remarkable advances over the past decade, transitioning from low-throughput experimental approaches to highly scalable platforms capable of...05-22-2026, 06:42 AM
Comment